Histone deacetylase inhibitors inhibit cervical cancer growth through Parkin acetylation-mediated mitophagy

Xin Sun; Yuhan Shu; Guiqin Ye; Caixia Wu; Mengting Xu; Ruilan Gao; Dongsheng Huang; Jianbin Zhang

doi:10.1016/j.apsb.2021.07.003

Histone deacetylase inhibitors inhibit cervical cancer growth through Parkin acetylation-mediated mitophagy

Acta Pharm Sin B. 2022 Feb;12(2):838-852. doi: 10.1016/j.apsb.2021.07.003. Epub 2021 Jul 21.

Authors

Xin Sun¹, Yuhan Shu², Guiqin Ye³, Caixia Wu⁴, Mengting Xu², Ruilan Gao⁵, Dongsheng Huang³, Jianbin Zhang⁴

Affiliations

¹ Department of Oncology, Cancer Center of Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou 310014, China.
² College of Biomedical Engineering & Instrument Science, Zhejiang University, Hangzhou 310028, China.
³ Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Hangzhou Medical College, Hangzhou 310014, China.
⁴ Clinical Research Institute, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou 310014, China.
⁵ Department of Hematology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, China.

Abstract

Parkin, an E3 ubiquitin ligase, plays a role in maintaining mitochondrial homeostasis through targeting damaged mitochondria for mitophagy. Accumulating evidence suggests that the acetylation modification of the key mitophagy machinery influences mitophagy level, but the underlying mechanism is poorly understood. Here, our study demonstrated that inhibition of histone deacetylase (HDAC) by treatment of HDACis activates mitophagy through mediating Parkin acetylation, leading to inhibition of cervical cancer cell proliferation. Bioinformatics analysis shows that Parkin expression is inversely correlated with HDAC2 expression in human cervical cancer, indicating the low acetylation level of Parkin. Using mass spectrometry, Parkin is identified to interact with two upstream molecules, acetylase acetyl-CoA acetyltransferase 1 (ACAT1) and deacetylase HDAC2. Under treatment of suberoylanilide hydroxamic acid (SAHA), Parkin is acetylated at lysine residues 129, 220 and 349, located in different domains of Parkin protein. In in vitro experiments, combined mutation of Parkin largely attenuate the interaction of Parkin with PTEN induced putative kinase 1 (PINK1) and the function of Parkin in mitophagy induction and tumor suppression. In tumor xenografts, the expression of mutant Parkin impairs the tumor suppressive effect of Parkin and decreases the anticancer activity of SAHA. Our results reveal an acetylation-dependent regulatory mechanism governing Parkin in mitophagy and cervical carcinogenesis, which offers a new mitophagy modulation strategy for cancer therapy.

Keywords: ACAT1; ACAT1, acetyl-CoA acetyltransferase 1; Acetylation; CCK-8, cell counting kit-8; COXⅣ, cytochrome c oxidase Ⅳ; Cervical cancer; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HDAC, histone deacetylase; HDAC2; HIF-1α, hypoxia inducible factor-1α; HSP60, heat shock protein 60 kDa; LC3, microtubule-associated proteins 1A/1B light chain 3; MFN2, mitofusion 2; MS, mass spectrometry; Mitophagy; PARK2, Parkin; PINK1, PTEN induced putative kinase 1; Parkin; ROS, reactive oxygen species; SAHA, suberoylanilide hydroxamic acid; TIM23, translocase of the inner membrane 23; TOMM20, translocase of outer mitochondrial membrane 20; TSA, trichostatin A; Tumor suppression; ULK1, unc-51 like autophagy activating kinase 1; Ubiquitination; VDAC1, voltage-dependent anion-selective channel protein 1.